![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Adherex Technologies, Inc. |
Information provided by: | Adherex Technologies, Inc. |
ClinicalTrials.gov Identifier: | NCT00264433 |
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin. This study will examine the clinical activity of ADH-1.
Condition | Intervention | Phase |
Neoplasms |
Drug: ADH -1 (Exherin™) |
Phase II |
MedlinePlus related topics: | Cancer |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | An Open-Label Phase 2a Study in Subjects With N-Cadherin Positive, Advanced or Recurrent Solid Tumors to Investigate the Safety and Efficacy of ADH-1 Administered Intravenously as a Single Agent (Adherex Protocol Number AHX-01-201) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Histologically proven advanced and/or metastatic solid tumor of one of the following histologies:
Exclusion Criteria:
History of:
United States, Florida | |||||
Florida Cancer Specialist | |||||
Fort Myers, Florida, United States, 33908 | |||||
United States, North Carolina | |||||
Lineberger Comprensive Cancer Center | |||||
Chapel Hill, North Carolina, United States, 27599 | |||||
Duke Comprehensive Cancer Centre | |||||
Durham, North Carolina, United States, 27703 | |||||
United States, Tennessee | |||||
Sarah Cannon Research Institute | |||||
Nashville, Tennessee, United States, 37203 | |||||
Chattanooga Oncology and Hematology Associates | |||||
Chattanooga, Tennessee, United States, 37404 | |||||
Canada, Alberta | |||||
Cross Cancer Institute | |||||
Edmonton, Alberta, Canada | |||||
Canada, British Columbia | |||||
BC Cancer Agency - Vancouver Centre | |||||
Vancouver, British Columbia, Canada | |||||
Canada, Nova Scotia | |||||
Centre for Clinical Research | |||||
Halifax, Nova Scotia, Canada | |||||
Canada, Ontario | |||||
The Ottawa Hospital Regional Cancer Center (TOHRCC) | |||||
Ottawa, Ontario, Canada, K1H 1C4 | |||||
Princess Margaret Hospital | |||||
Toronto, Ontario, Canada, M5G 2M9 | |||||
Canada, Quebec | |||||
McGill University Jewish General Hospital | |||||
Montreal, Quebec, Canada, H3T 1E2 |
Adherex Technologies, Inc. |
Adherex Technologies Inc. Corporate Homepage 
![]()   |
Study ID Numbers: | Adherex Protocol # AHX-01-201 |
First Received: | December 12, 2005 |
Last Updated: | August 3, 2007 |
ClinicalTrials.gov Identifier: | NCT00264433 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
![]() |